Huang, Xizhong,Peters, Malte,Schumacher, Karl Maria,Cao, Zhu Alexander,Gansert, Jennifer Lorraine,Chang, David Dong Eun
申请号：
AU2013292298
公开号：
AU2013292298A1
申请日:
2013.07.19
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
The present invention relates to a pharmaceutical combination comprising an alpha- isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine- 1,2-dicarboxylic acid 2-amide l-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin- 4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.
